Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

LWLu WangXMXiao‐Dong MoMHMingzhe Han

Discussion

Loading...

Member takes

Overview

Multicenter trial shows improved complete response in gastrointestinal aGVHD patients using mesenchymal stem cells, indicating viable treatment.

Key Points

  • The study achieved a complete response rate of 55.6% at day 28 among patients treated with mesenchymal stem cells for gastrointestinal aGVHD.
  • This multicenter trial involved 54 patients with steroid-refractory gastrointestinal graft-versus-host disease, demonstrating significant treatment outcomes.
  • Treatment utilizing second-line therapy with mesenchymal stem cells was assessed for response rates and safety over a four-week period.
  • Results suggest that mesenchymal stem cells may offer a promising option for managing steroid-refractory gastrointestinal aGVHD, warranting further investigation.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df06https://doi.org/10.1182/blood-2025-4237
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials2025 · 1 citations
  2. 2Mesenchymal stromal cells in the prophylaxis of graft vs host disease: A meta analysis2025
  3. 3An optimized MSC product promotes GvHD prophylaxis through exosome-mediated regulatory T cell induction2025 · 1 citations
  4. 4[Application of umbilical cord mesenchymal stem cells in the treatment of severe immune-mediated thrombocytopenia after allogeneic hematopoietic stem cell transplantation in children].2025
  5. 5CDCP1+ mesenchymal stem cells preferentially inhibit acute graft-versus-host disease(aGVHD)2025